{"prompt": "['Product: MK-3475', '128', 'Protocol/Amendment No.: 604-09', '[51]', 'Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor', 'inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-', 'containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A', '2001;98(24):13866-71.', '[52]', 'Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev', 'Immunol 2005;23:515-48.', '[53]', 'Sierocki JS, Hilaris BS, Hopfan S, Martini N, Barton D, Golbey RB, et al. cis-', 'Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for', 'small cell carcinoma of the lung. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1593-', '7.', '[54]', 'Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al.', 'Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus', 'cisplatin and etoposide versus alternation of these regimens in small-cell lung', 'cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855-61.', '[55]', 'Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al.', 'Randomized study of cyclophosphamide, doxorubicin, and vincristine versus', 'etoposide and cisplatin versus alternation of these two regimens in extensive', 'small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J', 'Clin Oncol. 1992 Feb; 10(2):282-91.', '[56]', 'Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al.', 'Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and', 'vincristine regimen in small-cell lung cancer: results from a randomized phase III', \"trial with 5 years' follow-up. J Clin Oncol. 2002 Dec 15;20(24):4665-72.\", '[57]', 'Chute JP, Venzon DJ, Hankins L, Okunieff P, Frame JN, Ihde DC, et al. Outcome', 'of patients with small-cell lung cancer during 20 years of clinical research at the', 'US National Cancer Institute. Mayo Clin Proc. 1997 Oct;72(10):901-12', '[58]', 'Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A', 'systematic review of the role of etoposide and cisplatin in the chemotherapy of', 'small cell lung cancer with methodology assessment and meta-analysis. Lung', 'Cancer. 2000 Oct;30(1):23-36.', '[59]', 'Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of', 'small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-', 'containing regimen versus a regimen without this alkylating agent. Br J Cancer.', '2000 Jul;83(1):8-15.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '129', 'Protocol/Amendment No.: 604-09', '[60]', 'Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., et al. Randomized', 'phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients', 'with previously untreated extensive-stage disease small-cell lung cancer. J Clin', 'Oncol 2006;24(13):2038-43', '[61]', 'Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase', 'III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-', 'stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG', 'S0124. J Clin Oncol. 2009 May 20;27(15):2530-5', '[62]', 'Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al.', 'First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung', 'cancer. N Engl J Med. In press 2018.', '[63]', 'Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III', 'Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo', 'Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin', 'Oncol. 2016 Nov 25;34:3740-8.', '[64]', 'Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et', 'al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and', 'irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group', 'study. Ann Oncol. 1994 Sep;5(7):601-7.', '[65]', 'Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al.', 'Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell', 'lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol.', '2012 May 10;30(14):1692-8.', '[66]', 'Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al.', 'Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign', 'trial. Br J Cancer. 1989 Apr;59(4):578-83.', '[67]', 'Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et', 'al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a', 'randomized trial. J Clin Oncol. 1993 Jul;11(7):1230-40', '[68]', 'Hanna NH, Sandier AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, et al.', 'Maintenance daily oral etoposide versus no further therapy following induction', 'chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell', 'lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002', 'Jan;13(1):95-102.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}